These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 21490745)

  • 1. Liposomal Tumor Targeting in Drug Delivery Utilizing MMP-2- and MMP-9-Binding Ligands.
    Penate Medina O; Haikola M; Tahtinen M; Simpura I; Kaukinen S; Valtanen H; Zhu Y; Kuosmanen S; Cao W; Reunanen J; Nurminen T; Saris PE; Smith-Jones P; Bradbury M; Larson S; Kairemo K
    J Drug Deliv; 2011; 2011():160515. PubMed ID: 21490745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted liposomal drug delivery in cancer.
    Medina OP; Zhu Y; Kairemo K
    Curr Pharm Des; 2004; 10(24):2981-9. PubMed ID: 15379663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A liposomal drug platform overrides peptide ligand targeting to a cancer biomarker, irrespective of ligand affinity or density.
    Gray BP; McGuire MJ; Brown KC
    PLoS One; 2013; 8(8):e72938. PubMed ID: 24009717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of tail-anchored protein chimeras to enhance liposomal cargo delivery.
    Abdelrehim A; Shaltiel L; Zhang L; Barenholz Y; High S; Harris LK
    PLoS One; 2019; 14(2):e0212701. PubMed ID: 30794671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From phage display to nanoparticle delivery: functionalizing liposomes with multivalent peptides improves targeting to a cancer biomarker.
    Gray BP; Li S; Brown KC
    Bioconjug Chem; 2013 Jan; 24(1):85-96. PubMed ID: 23186007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased tumor targeted delivery using a multistage liposome system functionalized with RGD, TAT and cleavable PEG.
    Mei L; Fu L; Shi K; Zhang Q; Liu Y; Tang J; Gao H; Zhang Z; He Q
    Int J Pharm; 2014 Jul; 468(1-2):26-38. PubMed ID: 24709209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor targeting using anti-her2 immunoliposomes.
    Park JW; Kirpotin DB; Hong K; Shalaby R; Shao Y; Nielsen UB; Marks JD; Papahadjopoulos D; Benz CC
    J Control Release; 2001 Jul; 74(1-3):95-113. PubMed ID: 11489487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Strategy Utilizing Extracellular Cysteine-Rich Domain of Membrane Receptor for Constructing d-Peptide Mediated Targeted Drug Delivery Systems: A Case Study on Fn14.
    Li Z; Xie J; Peng S; Liu S; Wang Y; Lu W; Shen J; Li C
    Bioconjug Chem; 2017 Aug; 28(8):2167-2179. PubMed ID: 28715634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pros and cons of the liposome platform in cancer drug targeting.
    Gabizon AA; Shmeeda H; Zalipsky S
    J Liposome Res; 2006; 16(3):175-83. PubMed ID: 16952872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-targeted delivery of liposome-encapsulated doxorubicin by use of a peptide that selectively binds to irradiated tumors.
    Lowery A; Onishko H; Hallahan DE; Han Z
    J Control Release; 2011 Feb; 150(1):117-24. PubMed ID: 21075152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective tumor targeting and enhanced anti-tumor effect of liposomes engrafted with peptides specific for tumor lymphatics and vasculature.
    Herringson TP; Altin JG
    Int J Pharm; 2011 Jun; 411(1-2):206-14. PubMed ID: 21443937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-targeted liposomal drug delivery mediated by a diseleno bond-stabilized cyclic peptide.
    Li C; Wang Y; Zhang X; Deng L; Zhang Y; Chen Z
    Int J Nanomedicine; 2013; 8():1051-62. PubMed ID: 23515368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro optimization of liposomal nanocarriers prepared from breast tumor cell specific phage fusion protein.
    Wang T; Kulkarni N; Bedi D; D'Souza GG; Papahadjopoulos-Sternberg B; Petrenko VA; Torchilin VP
    J Drug Target; 2011 Sep; 19(8):597-605. PubMed ID: 21275826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liposomal doxorubicin as targeted delivery platform: Current trends in surface functionalization.
    Makwana V; Karanjia J; Haselhorst T; Anoopkumar-Dukie S; Rudrawar S
    Int J Pharm; 2021 Jan; 593():120117. PubMed ID: 33259901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Future directions of liposome- and immunoliposome-based cancer therapeutics.
    Park JW; Benz CC; Martin FJ
    Semin Oncol; 2004 Dec; 31(6 Suppl 13):196-205. PubMed ID: 15717745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intelligent "Peptide-Gathering Mechanical Arm" Tames Wild "Trojan-Horse" Peptides for the Controlled Delivery of Cancer Nanotherapeutics.
    Shi NQ; Li Y; Zhang Y; Shen N; Qi L; Wang SR; Qi XR
    ACS Appl Mater Interfaces; 2017 Dec; 9(48):41767-41781. PubMed ID: 29161013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PEGylated liposomal doxorubicin targeted to α5β1-expressing MDA-MB-231 breast cancer cells.
    Shroff K; Kokkoli E
    Langmuir; 2012 Mar; 28(10):4729-36. PubMed ID: 22268611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A photo-responsive peptide- and asparagine-glycine-arginine (NGR) peptide-mediated liposomal delivery system.
    Xie X; Yang Y; Yang Y; Zhang H; Li Y; Mei X
    Drug Deliv; 2016 Sep; 23(7):2445-2456. PubMed ID: 25693640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of liposomal formulations for cell targeting.
    Nogueira E; Gomes AC; Preto A; Cavaco-Paulo A
    Colloids Surf B Biointerfaces; 2015 Dec; 136():514-26. PubMed ID: 26454541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel tumor-targeted thermosensitive liposomal cerasome used for thermally controlled drug release.
    Li S; Yin G; Pu X; Huang Z; Liao X; Chen X
    Int J Pharm; 2019 Oct; 570():118660. PubMed ID: 31491484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.